静脉联合腹腔热灌注化疗对晚期卵巢癌疗效及免疫功能的影响  

The effect of hyperthermic intraperitoneal perfusion chemotherapy on the efficacy and immune function of advanced ovarian cancer

作　　者：苏静[1] 

机构地区：[1]河南省三门峡市中心医院肿瘤内科,河南三门峡472000

出　　处：《中国现代医学杂志》2014年第10期107-109,共3页China Journal of Modern Medicine

摘　　要：目的评估静脉联合腹腔热灌注化疗对晚期卵巢癌疗效及免疫功能的影响。方法对该院收治的62例晚期卵巢癌患者采用随机数字表分成治疗组和对照组,治疗组31例采用腹腔热灌注化疗联合静脉化疗,对照组31例仅行全身静脉化疗,比较两组间不良反应、生存质量、免疫功能等。结果两组间术后不良反应及并发症比较,治疗组胃肠道不良反应高于对照组(P<0.05);治疗组生存质量的改善优于对照组(P<0.05);治疗组CD3+、CD4+和CD4+/CD8+各值较治疗前明显增高(P<0.05),对照组变化不明显。结论晚期卵巢癌患者行静脉联合腹腔热灌注化疗可改善患者生存质量,提高患者的细胞免疫功能。【Objective】To evaluate the clinical effect and immune function of early postoperative hyperthermic intraperitoneal perfusion chemotherapy（HIPC） for advanced ovarian cancer.【Methods】62 patients with advanced ovarian cancer were randomly divided into the therapeutic group with HIPC combined with intravenous chemotherapy（n =31） and the control group with intravenous chemotherapy only（n =31）. The adverse effects, life quality, immunological function of patients in two groups were compared. 【Results】The incidence of gastrointestinal adverse reactions in therapeutic group was higher than that in control group. The life quality of the therapeutic group was significantly improved compared with the control group. The levels of CD3＋, CD4＋, CD4＋/CD8＋in the therapeutic group were significantly higher than those before treatment（P ＆lt;0.05）, but no significant changes in the control group. 【Conclusions】HIPC combined with intravenous chemotherapy for advanced ovarian cancer can improve the quality of the patients life and immunological function.

关 键 词：腹腔热灌注化疗 晚期卵巢癌 静脉化疗 免疫功能 

分 类 号：R737.31[医药卫生—肿瘤]